Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

AN OFF-THE-SHELF VACCINE FOR TRIPLE-NEGATIVE BREAST CANCER

Obiettivo

Recent studies have demonstrated that mRNA-based vaccines targeting neoantigens, in combination with immune checkpoint blockade, can elicit robust anti-tumour responses across multiple cancer types. These advances have propelled the cancer vaccine market towards a projected growth from $7 billion to $19 billion by 2033. Despite this promise, critical technological hurdles remain. Current antigen selection strategies rely heavily on computationally predicted neoantigens, yet the majority fail to elicit detectable immune responses. Paradoxically, clinical evidence confirms that increasing the number of immunogenic tumour antigens per vaccine correlates with improved patient benefit. This underscores the urgent need for antigen repertoires that extend beyond mutation-derived neoantigens. Moreover, because neoantigens are patient-specific, current vaccines must be personalized, introducing substantial manufacturing costs and logistical complexity. TWISTAR addresses these limitations by advancing a next-generation vaccination strategy that incorporates not only somatic mutations but also functionally validated, shared tumour antigens derived from the ‘dark’ genome, which represents a rich and largely untapped source of immunogenic targets. By analysing tumour biopsies from triple-negative breast cancer (TNBC) patients, we have identified 10 such ‘dark’ antigens. In a co-development partnership with myNEO Therapeutics, we will now evaluate the immunogenicity of these shared antigens and assess how many TNBC patients are capable of mounting a T-cell response against them. If successful, these validated dark antigens will translate into an off-the-shelf vaccine that complements immune checkpoint blockade and reduces the recurrence risk of triple-negative breast cancer.

Campo scientifico (EuroSciVoc)

Questo progetto non è ancora stato classificato con EuroSciVoc.
Suggerisci i campi scientifici che ritieni più rilevanti e aiutaci a migliorare il nostro servizio di classificazione.

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2026-POC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

VIB VZW
Contributo netto dell'UE
€ 150 000,00
Indirizzo
SUZANNE TASSIERSTRAAT 1
9052 ZWIJNAARDE - GENT
Belgio
Regione
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Tipo di attività
Research Organisations
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)